Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury

Zhaoqing Li, Luning Qin, Xiaojian Xu, Ruolan Chen, Guoliang Zhang, Banghui Wang, Bing Li, Xian‐Ming ChuFrontiers in Immunology 2025 · DOI

Abstract: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the Coronavirus disease 2019 (COVID-19) pandemic, has posed significant healthcare challenges. In addition to respiratory complications, it has led to severe damage in other organs, particularly the cardiovascular system. Of which, myocardial injury is increasingly recognized as a most significant complication, contributing to the high mortality. Recent research indicates the pivotal role of immune dysregulation in mediating myocardial injury in patients infected with SARS-CoV-2. In this review, we provide a comprehensive analysis of the immune mechanisms involved in SARS-CoV-2-induced myocardial damage, focusing on the roles of key immune cells and molecules that contribute to this pathological process. Aiming at mitigating the myocardial injury of COVID-19, we review immune-based treatments under evaluation in preclinical and clinical trials. Along with talking about the similarities and differences in myocardial injury resulting from SARS-CoV-2, the Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus (SARS-CoV). This article provides a unique perspective on using past experiences to prevent myocardial injury in the face of ongoing virus mutations.

The Challenge of COVID-19 Myocardial Injury

Early in the pandemic, COVID-19 was viewed primarily through a pulmonary lens. However, clinicians quickly observed that myocardial injury (heart damage) was a massive predictor of mortality, often occurring even in patients without pre-existing heart conditions. The central challenge is a biological "catch-22": the body requires a robust immune response to clear the virus, but in severe cases, this response becomes dysregulated. This review synthesizes research to explain the specific molecular pathways where the immune system stops protecting the host and starts damaging heart tissue, leading to myocarditis, arrhythmias, and heart failure.

Mechanisms of Immune-Mediated Damage

The ACE2/Ang II/AT1 Axis and Cytokine Storm

A primary driver of cardiac damage is the interaction between SARS-CoV-2 and the ACE2 receptor. The virus uses ACE2 to enter cells, effectively depleting surface receptors. This creates an imbalance in the renin-angiotensin system, leading to an accumulation of Angiotensin II, which promotes vasoconstriction, inflammation, and cardiac fibrosis. Simultaneously, the recruitment of immune cells like macrophages and neutrophils can trigger a "cytokine storm"—a systemic hyper-inflammatory state that severely impacts cardiac function.

Schematic diagram of SARS-CoV-2 induced myocardial injury, illustrating the ACE2 pathway, immune cell activation, and the progression to a cytokine storm.

The Interferon Response and Viral Evasion

SARS-CoV-2 is a master of disguise, employing immune evasion tactics to delay the initial Type I Interferon (IFN) response. This delay allows viral loads to skyrocket, eventually triggering a compensatory hyperactivation of the innate immune system. This delayed but explosive response contributes significantly to the tissue damage observed in the heart.

The signaling pathway of interferon (IFN) induction and the JAK/STAT signaling cascade involved in the antiviral response.

Therapeutic Interventions

Research into mitigating these effects has identified several promising immunomodulatory strategies:

  • IL-6 Inhibition: Monoclonal antibodies like Tocilizumab have shown a statistically significant reduction in 28-day all-cause mortality in hospitalized patients by curbing the cytokine storm.
  • Stem Cell-Based Therapies: Mesenchymal Stem Cells (MSCs) and their derived exosomes act as immunomodulatory hubs. Rather than just replacing cells, they secrete paracrine factors that "calm" overactive macrophages and promote tissue repair.
  • Phytochemicals: Compounds such as Resveratrol have shown high inhibition rates of SARS-CoV-2 replication in in vitro models, suggesting potential as auxiliary treatments.

Future Perspectives and Limitations

While the acute phase of infection is increasingly well-understood, significant gaps remain regarding "Long COVID" and chronic cardiac dysfunction. Because the immune response involves a complex web of redundant cytokines, targeting a single molecule (like IL-6) is often insufficient; future work must focus on multi-target intervention schemes. Additionally, as the virus continues to mutate, the effectiveness of current immunomodulators and vaccines must be constantly re-evaluated to protect cardiovascular health.

Summary updated

Abstract

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the Coronavirus disease 2019 (COVID-19) pandemic, has posed significant healthcare challenges. In addition to respiratory complications, it has led to severe damage in other organs, particularly the cardiovascular system. Of which, myocardial injury is increasingly recognized as a most significant complication, contributing to the high mortality. Recent research indicates the pivotal role of immune dysregulation in mediating myocardial injury in patients infected with SARS-CoV-2. In this review, we provide a comprehensive analysis of the immune mechanisms involved in SARS-CoV-2-induced myocardial damage, focusing on the roles of key immune cells and molecules that contribute to this pathological process. Aiming at mitigating the myocardial injury of COVID-19, we review immune-based treatments under evaluation in preclinical and clinical trials. Along with talking about the similarities and differences in myocardial injury resulting from SARS-CoV-2, the Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus (SARS-CoV). This article provides a unique perspective on using past experiences to prevent myocardial injury in the face of ongoing virus mutations.
BibTeX
@inproceedings{li2025immune,
  author = {Zhaoqing Li and Luning Qin and Xiaojian Xu and Ruolan Chen and Guoliang Zhang and Banghui Wang and Bing Li and Xian‐Ming Chu},
  title = {{Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1561946},
}
Figure